ERBB2 and breast carcinoma: Numerous preclinical investigations of HER2-directed α-radioimmunotherapy in breast cancer have been reported, including with alternative antibody formats to IgGs such as single-domain antibodies and diabodies that are cleared primarily through the kidney (21).